ASH 2022 Conference Coverage
ASH 2022 Results From a Prespecified Analysis of the Pivotal Phase II Study ELM-2: Odronextamab in Patients With R/R FL Grade 1-3a
By
ASH 2022 Conference Coverage
FEATURING
Deepa Jagadeesh
By
ASH 2022 Conference Coverage
FEATURING
Deepa Jagadeesh
Login to view comments.
Click here to Login